316 related articles for article (PubMed ID: 26293246)
1. Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
Di Michele M; Stes E; Vandermarliere E; Arora R; Astorga-Wells J; Vandenbussche J; van Heerde E; Zubarev R; Bonnet P; Linders JT; Jacoby E; Brehmer D; Martens L; Gevaert K
J Proteome Res; 2015 Oct; 14(10):4179-93. PubMed ID: 26293246
[TBL] [Abstract][Full Text] [Related]
2. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
3. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
Hu J; Yu H; Kornev AP; Zhao J; Filbert EL; Taylor SS; Shaw AS
Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6067-72. PubMed ID: 21441104
[TBL] [Abstract][Full Text] [Related]
4. Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
Yao H; Sun Q; Zhu J
Arch Pharm (Weinheim); 2016 Oct; 349(10):808-815. PubMed ID: 27624806
[TBL] [Abstract][Full Text] [Related]
5. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
6. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
7. B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger.
Karki P; Li X; Schrama D; Fliegel L
J Biol Chem; 2011 Apr; 286(15):13096-105. PubMed ID: 21345796
[TBL] [Abstract][Full Text] [Related]
8. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.
Zhang J; Ji T
J Mol Model; 2017 Jan; 23(1):1. PubMed ID: 27921184
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
Eum KH; Ahn SK; Kang H; Lee M
Mol Cell Biochem; 2013 Jan; 372(1-2):65-74. PubMed ID: 22941213
[TBL] [Abstract][Full Text] [Related]
11. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
[TBL] [Abstract][Full Text] [Related]
12. Structural investigation of B-Raf paradox breaker and inducer inhibitors.
Arora R; Di Michele M; Stes E; Vandermarliere E; Martens L; Gevaert K; Van Heerde E; Linders JT; Brehmer D; Jacoby E; Bonnet P
J Med Chem; 2015 Feb; 58(4):1818-31. PubMed ID: 25611072
[TBL] [Abstract][Full Text] [Related]
13. RAF inhibitors that evade paradoxical MAPK pathway activation.
Zhang C; Spevak W; Zhang Y; Burton EA; Ma Y; Habets G; Zhang J; Lin J; Ewing T; Matusow B; Tsang G; Marimuthu A; Cho H; Wu G; Wang W; Fong D; Nguyen H; Shi S; Womack P; Nespi M; Shellooe R; Carias H; Powell B; Light E; Sanftner L; Walters J; Tsai J; West BL; Visor G; Rezaei H; Lin PS; Nolop K; Ibrahim PN; Hirth P; Bollag G
Nature; 2015 Oct; 526(7574):583-6. PubMed ID: 26466569
[TBL] [Abstract][Full Text] [Related]
14. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
[TBL] [Abstract][Full Text] [Related]
15. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling.
McKay MM; Ritt DA; Morrison DK
Curr Biol; 2011 Apr; 21(7):563-8. PubMed ID: 21458265
[TBL] [Abstract][Full Text] [Related]
16. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.
Holderfield M; Merritt H; Chan J; Wallroth M; Tandeske L; Zhai H; Tellew J; Hardy S; Hekmat-Nejad M; Stuart DD; McCormick F; Nagel TE
Cancer Cell; 2013 May; 23(5):594-602. PubMed ID: 23680146
[TBL] [Abstract][Full Text] [Related]
17. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.
Röring M; Herr R; Fiala GJ; Heilmann K; Braun S; Eisenhardt AE; Halbach S; Capper D; von Deimling A; Schamel WW; Saunders DN; Brummer T
EMBO J; 2012 May; 31(11):2629-47. PubMed ID: 22510884
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]